The GSPT2 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the GSPT2 gene has been disrupted. This product is generated in the SK-HEP-1 human hepatocellular carcinoma cell line, offering a heterogeneous knockout model for investigating the biological roles of GSPT2 in translation termination and mRNA surveillance. As a polyclonal population, it avoids clonal artifacts while maintaining robust target-gene disruption for functional studies.
The SK-HEP-1 cell line is a well-established model of human liver adenocarcinoma, derived from a malignant hepatocyte. These cells are widely used in hepatocellular carcinoma (HCC) research due to their tumorigenic properties and relevance to liver cancer biology. SK-HEP-1 cells display characteristic features of aggressive HCC, including aberrant signal transduction and dysregulated cell cycle control, making them an appropriate host for studying oncogenic mechanisms and therapeutic targets.
GSPT2 encodes eRF3b, a GTPase that partners with eRF1 (ETF1) to catalyze translation termination at stop codons. Beyond termination, GSPT2 is a critical mediator of nonsense-mediated mRNA decay (NMD), where it interacts with UPF1 and the SURF complex to target aberrant transcripts for degradation. The expression and activity of GSPT2 are regulated by upstream signals including E2F transcription factors and mTOR signaling, linking its function to nutrient and stress responses. GSPT2 regulates cyclin D1 and BCL2 family proteins, thereby controlling G1/S transition and apoptosis. GSPT2 also interacts with PABPC1 and the NMD factor SMG6, integrating translation termination with mRNA quality control.
In SK-HEP-1 hepatocellular carcinoma cells, disruption of GSPT2 is expected to impair translation termination fidelity and activate NMD pathways, leading to altered proteostasis and changes in gene expression. Given the regulatory connection between GSPT2 and cell cycle proteins like cyclin D1, as well as apoptotic regulators of the BCL2 family, knockout cells are likely to exhibit aberrant proliferation and survival phenotypes. This model therefore provides a relevant system for dissecting how translation control and mRNA surveillance contribute to the malignant phenotype of hepatocytes. It also serves as a platform for evaluating the therapeutic potential of targeting the translation machinery in liver cancer.
Researchers can utilize the GSPT2 Knockout SK-HEP-1 Polyclonal Cells in a variety of experimental settings, including Western blotting and RT-qPCR to confirm knockout effects, RNA-seq for transcriptome-wide analysis, and nonsense-mediated decay reporter assays to assess NMD activity. Functional studies can employ flow cytometry for cell cycle and apoptosis profiling, proliferation assays, polysome profiling to examine ribosome dynamics, and co-immunoprecipitation to probe protein interactions. This model is suited for translation termination studies, NMD research, hepatocellular carcinoma functional genomics, and drug target validation. For technical inquiries or additional information, please contact Ascent Research.
